Yesafili - Drug Monograph

Introduction

Yesafili (aflibercept) is a recombinant fusion protein biosimilar to aflibercept (reference product: Eylea), classified as an anti–vascular endothelial growth factor (anti-VEGF) agent. It is administered by intravitreal injection and is used primarily in the management of neovascular (wet) age-related macular degeneration and other retinal vascular diseases characterized by abnormal angiogenesis or vascular leakage. Its clinical relevance lies in providing a potentially lower-cost therapeutic option with the same molecular target and clinical profile as the reference product.

Drug Class and Overview

• Class: Anti-VEGF biologic; recombinant fusion protein composed of VEGF receptor 1 (VEGFR-1) and VEGF receptor 2 (VEGFR-2) extracellular domains fused to the Fc portion of human IgG1.
• Related agents: Ranibizumab (Lucentis), bevacizumab (Avastin, used off-label intravitreally), brolucizumab (Beovu), faricimab (Vabysmo).
• Distinguishing features: Unlike monoclonal anti-VEGF antibodies, aflibercept acts as a "decoy receptor" that binds VEGF-A, VEGF-B, and placental growth factor (PlGF). Yesafili is approved as a biosimilar, not as an interchangeable product (interchangeability status should be verified at the time of prescribing).

Mechanism of Action

Aflibercept binds VEGF-A (all isoforms), VEGF-B, and PlGF with high affinity, preventing these ligands from interacting with their endogenous receptors (VEGFR-1 and VEGFR-2) on endothelial cells. By blocking VEGF-mediated signaling, the drug:

• Inhibits pathologic neovascularization
• Reduces vascular leakage and edema
• Decreases inflammatory infiltration associated with VEGF-driven retinal pathology

This produces stabilization or improvement of visual acuity in conditions driven by choroidal or retinal neovascularization and vascular leakage.

Indications

Approved indications (mirroring the reference product aflibercept):

• Neovascular (wet) age-related macular degeneration (wet AMD)
• Macular edema following retinal vein occlusion (RVO; branch and central)
• Diabetic macular edema (DME)
• Diabetic retinopathy (DR)

Dosage and Administration

• Route: Intravitreal injection only; must be administered by a qualified ophthalmologist/retinal specialist under aseptic conditions.
• Adult dose: 2 mg (0.05 mL of 40 mg/mL solution) per affected eye.
• Typical regimens:
• Wet AMD: 2 mg every 4 weeks (monthly) for the first 3 months, then every 8 weeks; some patients may extend to 12-week intervals based on response.
• DME/DR: 2 mg every 4 weeks for the first 5 injections, then every 8 weeks.
• RVO: 2 mg every 4 weeks.
• Renal/hepatic adjustment: No dose adjustment required based on systemic exposure (systemic absorption is minimal).
• Pediatric use: Safety and effectiveness in pediatric patients have not been established.
• Geriatric use: No overall differences in safety/efficacy have been consistently demonstrated; use per standard adult dosing.
• Pregnancy/lactation: Limited data; use only if potential benefit justifies potential risk to the fetus. Caution in nursing mothers (consider withholding nursing or the drug).

Pharmacokinetics

• Absorption: Following intravitreal injection, systemic exposure is low but detectable.
• Distribution: Locally distributed within the eye; systemic distribution is limited.
• Metabolism: Expected to undergo standard protein catabolism via proteolytic degradation; not metabolized by CYP enzymes.
• Elimination: Primarily via proteolytic catabolism; systemic clearance is slow.
• Half-life: Intravitreal half-life is approximately 4–7 days (free aflibercept); systemic terminal half-life is approximately 5–6 days (approximate, based on reference product data).

Contraindications

• Ocular or periocular infections (active)
• Active intraocular inflammation
• Known hypersensitivity to aflibercept or any component of the formulation

Warnings and Precautions

• Endophthalmitis and intraocular infections: Intravitreal injections carry a risk of serious eye infection; proper aseptic technique is essential.
• Retinal detachment / tear: Patients should be monitored for rhegmatogenous retinal detachment.
• Increased intraocular pressure (IOP): Acute rise in IOP can occur within 60 minutes of injection; monitor perfusion to the optic nerve head.
• Arterial thromboembolic events (ATEs): Anti-VEGF agents carry a theoretical risk of ATEs (e.g., stroke, MI); use with caution in patients with known risk factors.
• Hypersensitivity reactions: May occur; discontinue if severe.
• Immunogenicity: As a therapeutic protein, anti-drug antibodies may develop; clinical significance is uncertain.

Drug Interactions

• Drug–drug interactions: No formal systemic drug interaction studies have been conducted due to negligible systemic exposure. Concomitant use of other intravitreal anti-VEGF agents is not recommended.
• Photodynamic therapy: Limited data on combined use with verteporfin; clinical practice generally avoids simultaneous administration.
• Management note: Because systemic absorption is minimal, systemic CYP-mediated interactions are unlikely.

Adverse Effects

Common (≥5%):

• Conjunctival hemorrhage
• Eye pain
• Cataract
• Vitreous detachment
• Vitreous floaters
• Increased intraocular pressure
• Conjunctival hyperemia

Serious/rare:

• Endophthalmitis
• Retinal detachment or tear
• Intraocular inflammation (uveitis, vitritis)
• Hypersensitivity reactions (including anaphylaxis)
• Arterial thromboembolic events (stroke, MI)
• Traumatic cataract from injection procedure

Monitoring Parameters

• Visual acuity and ophthalmologic examination (including fundus evaluation)
• Intraocular pressure (pre- and post-injection)
• Signs of intraocular infection or inflammation
• Slit-lamp and indirect ophthalmoscopic evaluation of the retina
• Systemic monitoring for signs of thromboembolic events in at-risk patients

Patient Education

• The medication is injected directly into the eye by a physician; report any eye pain, redness, blurred vision, or sensitivity to light immediately, as these may indicate infection.
• Attend all scheduled follow-up appointments; do not miss injection visits.
• Temporary visual blurring after injection is common; avoid driving until vision clears.
• Inform your doctor of any history of stroke, heart attack, or eye infections.
• Report new floaters, flashes of light, or a curtain-like shadow in vision (possible retinal detachment).
• Pregnant or breastfeeding patients should discuss risks with their provider before starting therapy.

Clinical Pearls

1. Yesafili is a biosimilar to aflibercept (Eylea); it shares the same amino acid sequence and mechanism but is not automatically interchangeable at the pharmacy level—confirm local regulatory status before substitution.
2. The "decoy receptor" design allows aflibercept to bind VEGF-A, VEGF-B, and PlGF, distinguishing it from monoclonal antibodies like ranibizumab and bevacizumab.
3. Endophthalmitis is the most feared complication of any intravitreal anti-VEGF injection; rigorous aseptic technique and prompt recognition are critical.
4. Dosing intervals can often be extended (treat-and-extend or as-needed regimens) in stable wet AMD patients, reducing treatment burden.
5. Systemic absorption is minimal, so systemic drug–drug interactions are uncommon, but arterial thromboembolic risk remains a class-wide concern.
6. Biosimilars like Yesafili expand access to anti-VEGF therapy by potentially lowering cost, but they must meet rigorous comparability standards in efficacy, safety, and immunogenicity.

References

1. U.S. Food and Drug Administration. Yesafili (aflibercept) Prescribing Information. 2024.
2. U.S. Food and Drug Administration. Eylea (aflibercept) Prescribing Information. Regeneron Pharmaceuticals.
3. American Academy of Ophthalmology. Age-Related Macular Degeneration Preferred Practice Pattern. 2024.
4. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice Pattern. 2023.
5. American Academy of Ophthalmology. Retinal Vein Occlusions Preferred Practice Pattern. 2023.
6. Heier JS, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012.
7. Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016.
8. Campochiaro PA, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results. Ophthalmology. 2014.
9. U.S. Food and Drug Administration. Biosimilar Development, Review, and Approval. FDA Guidance Documents.
10. European Medicines Agency. Aflibercept (Eylea) Summary of Product Characteristics.
11. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Anti-VEGF agents chapter.
12. Kanski & Bowling. Clinical Ophthalmology: A Systemic Approach. Anti-VEGF therapy section.